The short answer
Do not self-start L-5-HTP with imipramine. Official L-5-HTP guidance advises against use with antidepressants, and historical comparison studies do not establish combination safety.
What this answer covers
Oral L-5-hydroxytryptophan; benserazide-assisted treatment and unidentified hydroxytryptophan letter exposure are distinct.
- Supplement or preparation
- L-5-HTP
- Medication ingredient
- imipramine
The supplement precaution applies
Health Canada advises not to use L-5-HTP with antidepressants. Imipramine is an antidepressant, making this a relevant product warning even without a quantified combination risk.
The clinical trial tested a different question
The trial compared L-5-HTP plus benserazide against imipramine. It did not combine imipramine with L-5-HTP, and benserazide changes how the precursor is handled.
An old letter is not a safety recommendation
A letter title names imipramine, lithium and hydroxytryptophan, but its original clinical details were unavailable. It cannot establish a safe dose, absence of adverse effects or exact L-5-HTP preparation.
Review all mood products together
Bring every precursor and mood supplement to the prescriber. A dose gap has not been shown to remove serotonin-related concerns; seek urgent assessment for significant confusion, fever or muscle rigidity.
Evidence and practical considerations
Side effects & toxicity
Conditional avoidance/review follows exact supplement guidance; no invented exact-pair serotonin-syndrome event or rate.
- Exact scope
- Oral L-5-hydroxytryptophan; benserazide-assisted treatment and unidentified hydroxytryptophan letter exposure are distinct. with Exact oral imipramine hydrochloride tablets. RxNorm IN 5691/PIN 150816 hydrochloride; pamoate capsule is not assumed the same tested formulation. Desipramine metabolite evidence is distinguished from directly prescribed imipramine.
- Medication form and route
- oral
- Timing or duration
- Source-specific single-dose, repeated-dose and observational exposures distinguished.
What remains uncertain
- Comparison trial used alternatives; the combination letter is bibliographic only and includes lithium.
Factors that may matter: preparation and plant part; clinical indication; dose; other medicines; baseline alertness.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed oral imipramine.
Exact label warns about anticholinergic and sympathomimetic co-use, alcohol-related CNS effects and MAOI combinations. It does not explicitly name tryptophan, St John’s wort or serotonin syndrome.
How this applies: RxNorm IN 5691/PIN 150816 hydrochloride; pamoate capsule is not assumed the same tested formulation. Desipramine metabolite evidence is distinguished from directly prescribed imipramine.
No universal supplement interval, event rate or preparation equivalence established. Original label distinguishes warnings from measured pair-specific results.
Source 2: official product guidance
webprod.hc-sc.gc.ca · Source check Sep 10, 2026
Population: Adults considering oral L-5-HTP.
Advises not to use with antidepressants; gives serotonergic product precautions and drowsiness caution.
How this applies: The requested medicine is an antidepressant; this is a product-label precaution, not exact-pair clinical proof.
Does not quantify risk with each specific antidepressant or establish a safe supplement dose.
Source 3: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Thirty patients in the double-blind comparison, plus open studies.
No significant efficacy difference; gastrointestinal effects with L-5-HTP and dry mouth/tremor with imipramine.
How this applies: Only the named drug, preparation, route and measured endpoints apply.
Not co-use of imipramine and L-5-HTP. Decarboxylase inhibitor co-treatment differs from ordinary supplements.
Source 4: original letter record
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Indexed case-report letter.
Bibliographic record identifies a combination-treatment letter.
How this applies: Only the named drug, preparation, route and measured endpoints apply.
No abstract; publisher access returned 403. Route, exact stereoisomer, doses, response and adverse events not established from original text.
Source 5: current oral product label
medicines.org.uk · Source check Sep 10, 2026
Population: Patients prescribed oral imipramine hydrochloride solution.
Warns about serotonin syndrome with other serotonergic agents and anticholinergic combinations.
How this applies: Ingredient pharmacodynamic warning context; formulation-specific dose instructions are not transferred.
Does not specifically name the requested supplements or establish tablet/solution pharmacokinetic equivalence.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Current exact available claims adjudicated using original captures and explicit identity and comparator limits. | |
| Research summary published |
Article revision: dbe30779b1a4bf70
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.